Sight Sciences/$SGHT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Sight Sciences
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
- Ticker
- $SGHT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 186
- Headquarters
- Menlo Park, United States
- Website
- www.sightsciences.com
Sight Sciences Metrics
BasicAdvanced
$611M
-
-$0.52
2.40
-
Price and volume
Market cap
$611M
Beta
2.4
52-week high
$11.60
52-week low
$3.38
Average daily volume
392K
Financial strength
Current ratio
5.039
Quick ratio
4.508
Long term debt to equity
0.725
Total debt to equity
0.857
Interest coverage (TTM)
-3.47%
Profitability
EBITDA (TTM)
-17.482
Gross margin (TTM)
87.74%
Net profit margin (TTM)
-32.13%
Operating margin (TTM)
-20.25%
Effective tax rate (TTM)
-0.21%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
-10.11%
Return on equity (TTM)
-50.07%
Valuation
Price to revenue (TTM)
6.735
Price to book
12.35
Price to tangible book (TTM)
12.35
Price to free cash flow (TTM)
-35.202
Free cash flow yield (TTM)
-2.84%
Free cash flow per share (TTM)
-0.312
Growth
Revenue change (TTM)
16.23%
Earnings per share change (TTM)
-41.36%
3-year revenue growth (CAGR)
2.18%
3-year earnings per share growth (CAGR)
-25.63%
What the Analysts think about Sight Sciences
Analyst ratings (Buy, Hold, Sell) for Sight Sciences stock.
Analyst projections of the future price of Sight Sciences stock.
Bulls say / Bears say
Third-quarter revenue rose 25% year on year, and Sight Sciences lifted its 2026 revenue forecast to $92–93 million, implying growth of 19–20%. (Sight Sciences)
TearCare is gaining commercial traction: dry-eye revenue reached a record $3.9 million in the third quarter, up 45% sequentially, as more reimbursed procedures drove higher sales of its repeat-use treatment lids. (Sight Sciences, SEC)
Glaucoma growth could get a lift from Aetna coverage for OMNI and SION across about 25 million commercial lives, while the newly launched OMNI Ultra offers an upgraded product for surgeons. (Sight Sciences, Sight Sciences)
The company remains loss-making: it reported a $24.2 million net loss for the first nine months of 2026 and says it expects further losses. It had $40 million of debt, and warns that weak execution or cost control could force it to seek more financing. (SEC)
TearCare’s growth depends on reimbursement and market access, which remain limited to areas with established fee schedules. Wider payer coverage and consistent use will be needed to turn its early sales gains into a durable business. (SEC)
The $55.4 million patent award and ongoing royalty from Alcon are not settled: Alcon has appealed, and a remaining patent re-examination could adversely affect the judgment. That leaves the timing and value of any recovery uncertain. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
Sight Sciences Financial Performance
Revenues and expenses
Sight Sciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Sight Sciences News
AllArticlesVideos
Funds containing Sight Sciences
Fund name | Fund size | $SGHT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.